Patrick Soon - Feb 22, 2024 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Signature
/s/ Patrick Soon-Shiong,
Stock symbol
IBRX
Transactions as of
Feb 22, 2024
Transactions value $
$0
Form type
4
Date filed
2/26/2024, 04:36 PM
Previous filing
Jan 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Award $0 +343K $0.00 343K Feb 22, 2024 Common Stock 343K Direct F1, F2
transaction IBRX Stock Option (right to buy) Award $0 +1.19M $0.00 1.19M Feb 22, 2024 Common Stock 1.19M $5.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
F2 Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
F3 Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 22, 2024.

Remarks:

Executive Chairman, Global Chief Scientific and Medical Officer